BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cole HL, Pennycook S, Hayes PC. The impact of proton pump inhibitor therapy on patients with liver disease. Aliment Pharmacol Ther 2016;44:1213-23. [DOI: 10.1111/apt.13827] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Labenz C, Wörns MA, Adarkwah CC, Galle PR, Schattenberg JM, Kostev K. Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study. Aliment Pharmacol Ther 2020;52:1042-50. [PMID: 32729625 DOI: 10.1111/apt.16008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Current Opinion in Gastroenterology 2017;33:430-8. [DOI: 10.1097/mog.0000000000000392] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
3 Tran KT, Mcmenamin ÚC, Hicks B, Murchie P, Thrift AP, Coleman HG, Iversen L, Johnston BT, Lee AJ, Cardwell CR. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. Aliment Pharmacol Ther 2018;48:55-64. [DOI: 10.1111/apt.14796] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
4 Song HJ, Jiang X, Henry L, Nguyen MH, Park H. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:851-66. [PMID: 32172363 DOI: 10.1007/s00228-020-02854-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wu X, Zhang D, Yu Y, Lou L, Li X. Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies. Biosci Rep 2020;40:BSR20193890. [PMID: 32406491 DOI: 10.1042/BSR20193890] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Alhumaid S, Al Mutair A, Al Alawi Z, Zaidi ARZ, Rabaan AA, Elhazmi A, Al-Omari A. Proton pump inhibitors use and risk of developing spontaneous bacterial peritonitis in cirrhotic patients: A systematic review and meta-analysis. Gut Pathog 2021;13:17. [PMID: 33741033 DOI: 10.1186/s13099-021-00414-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bajaj JS, Acharya C, Fagan A, White MB, Gavis E, Heuman DM, Hylemon PB, Fuchs M, Puri P, Schubert ML, Sanyal AJ, Sterling RK, Stravitz TR, Siddiqui MS, Luketic V, Lee H, Sikaroodi M, Gillevet PM. Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. Am J Gastroenterol. 2018;113:1177-1186. [PMID: 29872220 DOI: 10.1038/s41395-018-0085-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 14.5] [Reference Citation Analysis]
8 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
9 Schiavon LL, Silva TE, Fischer J, Narciso-Schiavon JL. Letter: Proton pump inhibitors and prognosis of cirrhosis - searching for the balance point. Aliment Pharmacol Ther. 2017;45:378-379. [PMID: 27933687 DOI: 10.1111/apt.13873] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Bettinger D, Martin D, Rieg S, Schultheiss M, Buettner N, Thimme R, Boettler T. Treatment with proton pump inhibitors is associated with increased mortality in patients with pyogenic liver abscess. Aliment Pharmacol Ther 2018;47:801-8. [PMID: 29327781 DOI: 10.1111/apt.14512] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
11 Labenz C, Kostev K, Galle PR, Wörns MA, Labenz J, Tanislav C, Adarkwah CC. Proton pump inhibitor use is associated with a variety of infections in patients with liver cirrhosis. Medicine (Baltimore) 2020;99:e23436. [PMID: 33327272 DOI: 10.1097/MD.0000000000023436] [Reference Citation Analysis]
12 Shaw J, Bajaj JS. Editorial: should the inappropriate use of proton pump inhibitors be a quality assurance issue in cirrhotic patients? Aliment Pharmacol Ther 2017;45:476-7. [PMID: 28043093 DOI: 10.1111/apt.13875] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Imperatore N, Tortora R, Testa A, Gerbino N, Caporaso N, Rispo A. Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet. J Gastroenterol 2018;53:507-16. [DOI: 10.1007/s00535-017-1381-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
14 Chang TE, Huang YS, Perng CL, Huang YH, Hou MC. Use of proton pump inhibitors and the risk of hepatocellular carcinoma: A systematic review and meta-analysis. J Chin Med Assoc 2019;82:756-61. [PMID: 31335628 DOI: 10.1097/JCMA.0000000000000157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Sakamaki A, Kamimura K, Yokoo T, Osaki A, Yoshikawa S, Arao Y, Setsu T, Kamimura H, Waguri N, Takeuchi M, Funakoshi K, Terai S. The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan. Medicine (Baltimore) 2021;100:e26902. [PMID: 34397919 DOI: 10.1097/MD.0000000000026902] [Reference Citation Analysis]
16 Jun T, Ozbek U, Dharmapuri S, Hardy-Abeloos C, Zhu H, Lin JY, Personeni N, Pressiani T, Nishida N, Lee PC, Lee CJ, Hildebrand H, Nimkar N, Paul S, Fessas P, Naeem M, Bettinger D, Khan U, Saeed A, Huang YH, Kudo M, Rimassa L, Marron TU, Pinato DJ, Ang C. Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol 2021;13:17588359211010937. [PMID: 33995594 DOI: 10.1177/17588359211010937] [Reference Citation Analysis]
17 Li DK, Chung RT. Use of proton pump inhibitors in chronic liver diseases. Clin Liver Dis (Hoboken) 2017;10:148-51. [PMID: 30992776 DOI: 10.1002/cld.678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, Metselaar HJ, Monster-Simons MH, van Putten SAW, Taxis K, Borgsteede SD. Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018;84:1806-1820. [PMID: 29688583 DOI: 10.1111/bcp.13615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
19 Tantai XX, Yang LB, Wei ZC, Xiao CL, Chen LR, Wang JH, Liu N. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis. World J Gastroenterol 2019; 25(21): 2683-2698 [PMID: 31210719 DOI: 10.3748/wjg.v25.i21.2683] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]